What Amgen's deCODE Purchase Means for Drug Discovery

December 10, 2012 | Does Amgen's purchase of deCODE present a model for counteracting failure rates in drug discovery. Terry McGuire points out: "Amgen acquired deCODE for more than its patents, genetic testing business, or drug development projects—although there is plenty of value there. Amgen bought deCODE for its powerhouse research engine." Xconomy